Monoclonal antibodies targeting neutralizing epitopes on h7 influenza viruses
AssigneeTemasek Life Sciences Laboratory Limited
InventorsHwei-Sing Jimmy KWANG, Fang HE, Rajesh Kumar SUBASCHANDRABOSE
Life of this patent
Estimating the term…
Loading patent…
AssigneeTemasek Life Sciences Laboratory Limited
InventorsHwei-Sing Jimmy KWANG, Fang HE, Rajesh Kumar SUBASCHANDRABOSE
Estimating the term…
The present invention relates to the murine monoclonal antibody (mAb) 11B9 and to mAb 62 each of which target major neutralizing epitopes of influenza A H7 hemagglutinin and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H7 influenza using murine mAb 11B9, mAb 62 or fragments thereof. The present invention further relates to methods and kits for determining, identifying and/or quantifying (a) influenza A hemagglutinin in a sample or vaccine or (b) an antibody against influenza A hemagglutinin.
A monoclonal antibody or antibody fragment which specifically binds to a neutralizing conformational epitope of H7 hemagglutinin, wherein the neutralizing conformational epitope (a) is comprised of amino acid 136Ser, 137Gly and amino acid 227Glu or (b) is comprised of amino acid 175Lys and amino acid 227Glu.
Monoclonal antibody 11B9 as produced by hybridoma 11B9 which is deposited with Cell Bank Australia with Accession Number CBA20120022.
Monoclonal antibody 62 as produced by hybridoma 62 which is deposited with Cell Bank Australia with Accession Number CBA20120023.
A kit for detecting an influenza A H7 subtype virus in a biological specimen which comprises a first antibody, wherein the first antibody is the monoclonal antibody or antibody fragment which specifically binds to a neutralizing conformational epitope of H7 hemagglutinin, wherein the neutralizing conformational epitope (a) is comprised of amino acid 136Ser, 137Gly and amino acid 227Glu or (b) is comprised of amino acid 175Lys and amino acid 227Glu together with instructions for performing an assay to detect the influenza A virus.
A composition comprising an agent and a pharmaceutically acceptable diluent or carrier, wherein the agent is the monoclonal antibody or antibody fragment which specifically binds to a neutralizing conformational epitope of H7 hemagglutinin, wherein the neutralizing conformational epitope (a) is comprised of amino acid 136Ser, 137Gly and amino acid 227Glu or (b) is comprised of amino acid 175Lys and amino acid 227Glu.
A kit for identifying and/or quantifying an immunogenic agent of an influenza A H7 subtype virus in a patient's sample or in a vaccine comprising an immunogenic agent of the influenza A H7 subtype virus, which kit comprises a first antibody, wherein the first antibody is the monoclonal antibody or antibody fragment which specifically binds to a neutralizing conformational epitope of H7 hemagglutinin, wherein the neutralizing conformational epitope (a) is comprised of amino acid 136Ser, 137Gly and amino acid 227Glu or (b) is comprised of amino acid 175Lys and amino acid 227Glu together with instructions for performing an assay to identify and/or quantify the immunogenic agent of the influenza A H7 subtype virus in the patient's sample or in the vaccine.
A method for detecting an antibody against an influenza A H7 subtype virus in a biological specimen which comprises:
A method for detecting the presence of influenza A H7 antigen or anti-H7 antibodies in a biological specimen which comprises
A kit for detecting the presence of influenza A H7 antigen or anti-H7 antibodies in a biological specimen which comprises
Dependencies are inferred from the claim text.